Integra Lifesciences (IART) Reaches New 12-Month High and Low at $66.66

Integra Lifesciences Holdings Corp (NASDAQ:IART) reached a new 52-week high and low on Thursday . The company traded as low as $66.66 and last traded at $66.32, with a volume of 8413 shares trading hands. The stock had previously closed at $66.52.

IART has been the topic of a number of recent analyst reports. Cantor Fitzgerald reissued a “hold” rating and issued a $59.00 price objective on shares of Integra Lifesciences in a research note on Tuesday. Oppenheimer set a $74.00 price objective on shares of Integra Lifesciences and gave the company a “buy” rating in a research note on Friday, June 1st. JPMorgan Chase & Co. lifted their price objective on shares of Integra Lifesciences from $57.00 to $65.00 and gave the company a “neutral” rating in a research note on Tuesday, May 22nd. BidaskClub raised shares of Integra Lifesciences from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, May 8th. Finally, Zacks Investment Research raised shares of Integra Lifesciences from a “hold” rating to a “buy” rating and set a $69.00 price objective on the stock in a research note on Tuesday, May 1st. Eleven analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $60.69.

The company has a market capitalization of $5.76 billion, a price-to-earnings ratio of 34.23, a price-to-earnings-growth ratio of 1.97 and a beta of 0.65. The company has a debt-to-equity ratio of 1.77, a quick ratio of 1.66 and a current ratio of 2.53.

Integra Lifesciences (NASDAQ:IART) last posted its earnings results on Wednesday, April 25th. The life sciences company reported $0.58 earnings per share for the quarter, topping analysts’ consensus estimates of $0.49 by $0.09. The firm had revenue of $357.10 million for the quarter, compared to analysts’ expectations of $349.15 million. Integra Lifesciences had a net margin of 5.39% and a return on equity of 17.90%. The company’s revenue was up 38.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.39 earnings per share. equities analysts predict that Integra Lifesciences Holdings Corp will post 2.41 earnings per share for the current fiscal year.

In other Integra Lifesciences news, VP Daniel L. Reuvers sold 1,000 shares of the business’s stock in a transaction on Monday, April 30th. The shares were sold at an average price of $62.04, for a total transaction of $62,040.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 5.10% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of IART. Westwood Holdings Group Inc. bought a new stake in shares of Integra Lifesciences during the first quarter worth $32,180,000. Champlain Investment Partners LLC grew its stake in shares of Integra Lifesciences by 7.6% in the first quarter. Champlain Investment Partners LLC now owns 4,997,595 shares of the life sciences company’s stock worth $276,567,000 after purchasing an additional 351,520 shares during the last quarter. BlackRock Inc. grew its stake in shares of Integra Lifesciences by 3.4% in the fourth quarter. BlackRock Inc. now owns 8,135,552 shares of the life sciences company’s stock worth $389,367,000 after purchasing an additional 269,484 shares during the last quarter. Broadfin Capital LLC grew its stake in shares of Integra Lifesciences by 321.1% in the fourth quarter. Broadfin Capital LLC now owns 330,600 shares of the life sciences company’s stock worth $15,823,000 after purchasing an additional 252,100 shares during the last quarter. Finally, Renaissance Technologies LLC grew its stake in shares of Integra Lifesciences by 92.4% in the fourth quarter. Renaissance Technologies LLC now owns 405,800 shares of the life sciences company’s stock worth $19,422,000 after purchasing an additional 194,900 shares during the last quarter. 79.49% of the stock is currently owned by hedge funds and other institutional investors.

Integra Lifesciences Company Profile

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply